Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study-Reference-Cited by-同舟云学术

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study

Published:2022-04 Issue: Volume:Volume 17 Page:967-976
ISSN:1178-2005
Container-title:International Journal of Chronic Obstructive Pulmonary Disease
language:en
Short-container-title:COPD

Author:

Hsieh Meng-Jer^ORCID,Chen Ning-Hung,Cheng Shih-Lung,Tao Chi-Wei,Wei Yu-Feng^ORCID,Wu Yao-Kuang^ORCID,Chan Ming-Cheng,Liu Shih-Feng^ORCID,Hsu Wu-Huei,Yang Tsung-Ming,Lin Ming-Shian,Liu Ching-Lung,Kuo Ping-Hung^ORCID,Tsai Ying-Huang

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pulmonary and Respiratory Medicine,General Medicine

Reference19 articles.

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease—2020 report. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed April 1, 2022.

2. World Health Organization. The top 10 causes of death. WHO. Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death; 2020. Accessed 23 November, 2020.

3. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

4. Ministry of Health and Welfare, Taiwan. Taiwan’s Leading Causes of Death in 2016. Ministry of Health and Welfare; 2017. Available from: https://www.mohw.gov.tw/cp-3425-33347-2.html. Accessed November 23, 2018.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisión narrativa de la terapia inhalatoria en la EPOC;Medicina de Familia. SEMERGEN;2024-10

2. Prediction of Hospitalization and Mortality in Patients with Chronic Obstructive Pulmonary Disease with the New Global Initiative for Chronic Obstructive Lung Disease 2023 Group Classification: A Prospective Cohort and a Retrospective Analysis;International Journal of Chronic Obstructive Pulmonary Disease;2023-10

3. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England;International Journal of Chronic Obstructive Pulmonary Disease;2023-09

4. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD;Chest;2023-04

5. Asthma and COPD: A Focus on β-Agonists – Past, Present and Future;Handbook of Experimental Pharmacology;2023